2022
Incidence of Alopecia in Treatment of Women With Uterine Fibroids: Results of Two Phase 3 Trials of Linzagolix [A104]
Al-Hendy A, Taylor H, Catherino W, Stewart E, Bestel E, Garner E. Incidence of Alopecia in Treatment of Women With Uterine Fibroids: Results of Two Phase 3 Trials of Linzagolix [A104]. Obstetrics And Gynecology 2022, 139: 30s-30s. DOI: 10.1097/01.aog.0000826736.08037.1b.Peer-Reviewed Original ResearchPhase 3 trialUterine fibroidsGnRH antagonistHair lossPlacebo-controlled phase 3 trialUterine fibroid-related symptomsFibroid-related symptomsIncidence of alopeciaOral GnRH antagonistPooled safety analysisTreatment of womenConcomitant therapyTreatment discontinuationStudy drugWeek 52Mild alopeciaWeek 24Benign disorderSimilar incidenceLinzagolixSuppression dosesAlopeciaFibroidsTrialsTreatment
2010
Does obesity affect the vaginal hysterectomy outcomes?
Harmanli O, Dandolu V, Isik E, Panganamamula U, Lidicker J. Does obesity affect the vaginal hysterectomy outcomes? Archives Of Gynecology And Obstetrics 2010, 283: 795-798. PMID: 20237934, DOI: 10.1007/s00404-010-1422-4.Peer-Reviewed Original ResearchConceptsNon-obese womenVaginal hysterectomyPerioperative outcomesPerioperative hemoglobin changePrevious pelvic surgeryRetrospective cohort studyEffect of obesityHospital stayPerioperative complicationsTransfusion rateCohort studyObese womenPerioperative indexesSurgical complicationsSurgical indicationsUterine weightHysterectomy outcomesOperative timeBenign disorderPelvic surgeryHemoglobin changeMedical conditionsHysterectomyWomenObese
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply